These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Increased expression of CD40 ligand on activated T cells of patients with colon cancer. Büning C; Krüger K; Sieber T; Schoeler D; Schriever F Clin Cancer Res; 2002 Apr; 8(4):1147-51. PubMed ID: 11948126 [TBL] [Abstract][Full Text] [Related]
8. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer. Kumar S; Chang EY; Frankhouse J; Dorsey PB; Lee RG; Johnson N Arch Surg; 2009 Sep; 144(9):835-40. PubMed ID: 19797108 [TBL] [Abstract][Full Text] [Related]
9. [Carcinoembryonic antigen in serum and the tissue of patients with colon cancer]. Odagiri E; Jibiki K; Shinozaki H; Nakamura S; Demura R; Demura H; Suzuki H Gan No Rinsho; 1984 Oct; 30(13):1680-5. PubMed ID: 6513021 [TBL] [Abstract][Full Text] [Related]
10. The current status of colon cancer immunology. Deasy JM Ir Med J; 1983 Sep; 76(9):393-5. PubMed ID: 6363339 [No Abstract] [Full Text] [Related]
12. Factors in the control of colon and rectal cancer. Ramsey HE Md State Med J; 1974 Mar; 23(3):43-6. PubMed ID: 4816341 [No Abstract] [Full Text] [Related]
13. Status of colon cancer vaccines. [An interview with Michael Morse by H&O]. Morse MA Clin Adv Hematol Oncol; 2008 Nov; 6(11):789, 794. PubMed ID: 19194360 [No Abstract] [Full Text] [Related]
14. The potential for improved outcome in patients with hepatic metastases from colon cancer: a population-based study. Sjövall A; Järv V; Blomqvist L; Singnomklao T; Cedermark B; Glimelius B; Holm T Eur J Surg Oncol; 2004 Oct; 30(8):834-41. PubMed ID: 15336728 [TBL] [Abstract][Full Text] [Related]
15. [Endoscopic monitoring of patients after partial colon resection for colonic cancer]. Sygula-Siebert E Med Welt; 1982 Oct; 33(42):1474-6. PubMed ID: 7176870 [No Abstract] [Full Text] [Related]
16. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Scanlan MJ; Welt S; Gordon CM; Chen YT; Gure AO; Stockert E; Jungbluth AA; Ritter G; Jäger D; Jäger E; Knuth A; Old LJ Cancer Res; 2002 Jul; 62(14):4041-7. PubMed ID: 12124339 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma. Lumsden AJ; Codde JP; Van der Meide PH; Gray BN Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226 [TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of tissue polypeptide antigen in patients with esophageal, stomach and colon cancer]. Ogoshi K; Kondo Y; Akiba Y; Sugihara T; Ko S; Noto T; Makuuchi H; Tajima T; Mitomi T Gan No Rinsho; 1984 Aug; 30(10):1299-302. PubMed ID: 6481966 [TBL] [Abstract][Full Text] [Related]
19. Some parameters of cell-mediated immunity in colon cancer patients. Markova R; Argirova R; Boeva M Neoplasma; 1980; 27(1):43-6. PubMed ID: 6966380 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line. Li YY; Hsieh LL; Tang RP; Liao SK; Yeh KY Hum Immunol; 2009 Mar; 70(3):151-8. PubMed ID: 19272324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]